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Plants by virtue of its composition of containing multiple constituents developed during its growth under various
environmental stresses providing a plethora of chemical families with medicinal utility. Researchers are exploring
this wealth and trying to decode its utility for enhancing health standards of human beings. Diabetes is dreadful
lifestyle disorder of 21st century caused due to lack of insulin production or insulin physiological unresponsiveness.
The chronic impact of untreated diabetes significantly affects vital organs. The allopathic medicines have five classes
of drugs, or otherwise insulin in Type I diabetes, targeting insulin secretion, decreasing effect of glucagon,
sensitization of receptors for enhanced glucose uptake etc. In addition, diet management, increased food fiber
intake, Resistant Starch intake and routine exercise aid in managing such dangerous metabolic disorder. One of the
key factors that limit commercial utility of herbal drugs is standardization. Standardization poses numerous
challenges related to marker identification, active principle(s), lack of defined regulations, non-availability of
universally acceptable technical standards for testing and implementation of quality control/safety standard
(toxicological testing). The present study proposed an integrated herbal drug development & standardization
model which is an amalgamation of Classical Approach of Ayurvedic Therapeutics, Reverse Pharmacological
Approach based on Observational Therapeutics, Technical Standards for complete product cycle, Chemi-informatics,
Herbal Qualitative Structure Activity Relationship and Pharmacophore modeling and, Post-Launch Market Analysis.
Further studies are warranted to ensure that an effective herbal drug standardization methodology will be
developed, backed by a regulatory standard guide the future research endeavors in more focused manner.
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Herbal drugs have been used since the inception of hu-
man beings on this planet and as a result is almost as
old as life itself. In the modern world, the traditional
(herbal) medicines assumed a significant proportion of >
83 billion dollars annual production (2008), increasing
exponentially [1]. In developing countries, 70-95% of the
population relies on herbal medicines for primary care
mainly due to cost imperatives or unavailability of* Correspondence: rajesharoradr@gmail.com
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reproduction in any medium, provided the orconventional drugs. In India, in spite of over 80% of the
population dependent upon herbal drugs; it occupies less
than 2.5% of the global market share. On the other hand,
> 60% market share is being controlled by European
Union and North America while 16% being shared by
Japan and rest 19% by ASEAN countries [2,3].
Herbal medicines, containing active ingredients in
complex chemical mixtures developed as crude fractions,
extracted from aerial or underground parts of plant or
other plant material or combination thereof, are widely
used in health-care or as dietary supplements. One of the
major drawbacks of these medicines is limited bioavailabil-
ity, being poorly absorbed if taken orally [4-6]. AccordingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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about 80% of the world population still uses herbs and
other traditional medicines for fulfilling their primary
health care needs [7]. It is essential to understand that its
effectiveness may vary and it might interact with other
drugs leading to contraindications. Safety considerations
regarding toxicological analysis, pre-clinical and clinical
trials are essential prior to adoption of any herbal medi-
cine. At present, herbal formulations have reached wide-
spread acceptability as therapeutic agents for diabetics,
arthritics, liver diseases, cough remedies, memory en-
hancers and adoptogens [8]. In spite of such wide accept-
ability, the number of standardized herbal drugs is less
due to lack of regulatory standards and implementation
protocols.
Standardization requires a lead/natural plant product
to be authenticated at origin itself by adoption of good
agricultural practices [9]/ collection strategies from wild
and good manufacturing practices for extraction modes
and related parameters [10-13]. The acceptance of lead
as a future drug candidate requires correct identification,
authentication and concentration of active principle
[14,15]/ defined quantities of active components in poly
herbal formulations [16,17]. The regulatory approvals to
ascertain consistent chemical profile and biological activ-
ity of future drug candidate [18] includes a) quality as-
surance by determining adulterants, pesticides residue,
aflatoxin content, bacterial/fungal growth and heavy
metals contamination etc. [9]; b) prevention of adverse
reactions by evaluating pharmacodynamics, pharmaco-
kinetics, dosage, stability, self-life and toxicity (acute/
chronic) etc. [19]; c) reproducibility by repetitive testing
using different batches to control batch-to-batch vari-
ation and development of standard assay markers [17]
and; d) chemiinformatic approaches to ensure that
pharmacological profiles matches with the activity pro-
files of active constituents of drug itself.
Diabetes, a dreadful lifestyle metabolic disorder with
every 5th Indian as diabetic by 2025 (40 million diabetics
in India expected to be 70 million by 2025) [20]. It is a
silent epidemic that directly affects glucose catabolism
leading to energy yielding changes. The chronic effects
include blindness (2%); visual handicap (10%); diabetic
retinopathy and neuropathy; sensory loss and damage to
limbs [21]. In India, the difference in number of cases
being affected in urban population with respect to rural
is 8% because of changes in lifestyle and consumption
patterns [22]. Globally Type I diabetes, an autoimmune
disorder in which beta cells are not functional, affects
10% of diabetic population while 90% cases falls into cat-
egory of Type II wherein down regulation of receptors
leads to insulin non-responsiveness [23]. Type II dia-
betes produces mild symptoms like fatigue, increased
thirst and hunger, weight loss, blurred vision, frequenturination and slow healing of wounds or sores, and can
be controlled with a healthy diet, exercise and weight
loss. The genetic defects at neonatal level or syndromes
causing beta cells destruction leads to various complica-
tions such as maturity- onset diabetes of the young
(MODY) or neonatal diabetes mellitus (NDM) [23].
There are more than 1000 plants which are used in anti
diabetic herbal formulations and among them about 100
plants have been scientifically validated [24]. However,
no single approved herbal drug is available till date for
mass usage. It is essentially due to lack of standardiza-
tion methodologies adopted prior to development of
drug.
The present review focuses on the herbal standardiza-
tion models that can be useful for development of evi-
dence based holistic natural plant products with a
special case study on ‘management of diabetes’. It pro-
vides an in depth analysis of limitations of treatment
methodologies; available herbal alternatives; contraindi-
cations vs. complications criterion and novel models for
standardization of herbal drugs.
Diabetes: a dreadful lifestyle disorder of 21st century
India is amongst the top most countries followed by
China and USA where Diabetes still plagues the society
with 32, 26 and 18 million cases respectively [25]. Stud-
ies suggest that the average rate of incidence of diabetes
in India has reached a value of 7% annually as a result of
growing urbanization and changing lifestyle patterns
[26]. The average rate at which diabetes causes upsetting
loss to the world economy has been figured out to be
12.5% annually [27]. The major causes of diabetes in-
cludes either complete absence of insulin hormone
(Type I) due to auto-immune disorder/genetic defects/
abnormal physiology (unknown causes) or inadequate
biological response towards insulin (Type II) due to
down-regulation of receptors (usually in adults due to
obesity or other lifestyle factors) [28-30], leading to ele-
vated blood glucose levels [24]. Such elevated levels, if
not controlled/managed by external supplementation,
leads to energy starvation and deleterious effects on
multiple organs like kidney, heart, eyes or nerves and
50% of the diabetic people show such complications at
some later stages of chronic metabolic disorder [21,31].
In Type I diabetes, an increased urge of thirst, con-
stant hunger, weight loss, extreme fatigue, blurred vision
and diabetic ketoacidosis may occur while in case of
Type II diabetes, frequent urination, persistent hunger,
distorted vision, weight loss and extreme exhaustion are
primary symptoms. Secondary complications may in-
clude a genetic defect of the β cell leading to genetic al-
terations such as Maturity Onset Diabetes of the Young
(MODY) or Neonatal Diabetes mellitus (NDM), conse-
quently making the body incapable of controlling the
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of the causative factors responsible for the pathophysi-
ology of chronic diabetes includes free radical induced
oxidative stress, analogous to radiation-induced acute
multi-organ dysfunction syndrome [32,33]. In both
cases, advanced glycation end products (AGEs) [34,35]
are formed by non enzymatic glycosylation of proteins
and they tend to accumulate in body tissues, thereby
augmenting the process of free radical formation. This
consequently results in the progression of the disease
into a Multiorgan Dysfunction Syndrome (MODS),
thereby posing adverse effects on multiple organs in-
cluding liver, kidney, pancreas etc. [36]. Antioxidants of
either synthetic or herbal origin might be utilized in
neutralizing free radicals, thereby mitigating the impact
of such diseases.
Existing approaches for diabetes management
The basic treatment approach is to minimize elevated
blood sugar (glucose) level without causing abnormal
reduction (hypoglycemia) by using oral antidiabetic
drugs; insulin administration; nutritional dietary aid, diet
management and scheduled exercise.
WHO reports (1997) showed that between 20%-50%
of people with type II diabetes can control their blood
glucose levels by dietary modification alone [22]. More
than 50% of calorific value of human diet is fulfilled by
starch based foods. Starch contains amylose and amylo-
pectin in the ratio of 1:3. Extensive branching in amylo-
pectin and linear long chains of amylose typically resist
digestion and hence play a role in resistant starch (RS)
formation. Mechanisms and processes by which foods,
rich in fiber and resistant starch, exert their disease con-
trol properties are not well understood. Some of these
factors believed to have effects on rate of digestion and
absorption. These include source of food material, its
components, physical nature, presence of enzyme inhibi-
tors, anti-nutrients as well as processing methods [37].
The enzymes responsible for carbohydrate hydrolysis are
excluded by the fibre components in food thereby
slowing down the rate of hydrolysis, impersonating re-
sistant starch metabolism [38]. RS based diet related
study on humans depicted increased insulin sensitivity
in noninsulin-resistant subjects by changing both adi-
pose tissue and skeletal muscle metabolism can be
linked with elevated levels of systemic concentrations of
both ghrelin and SCFAs (short chain fatty acids) [39].
High amylose starches have potential of controlling
high-fat diet-induced obesity by modulating hepatic fatty
acid oxidation [40] while RS induces increase in the
levels of anti-diabetic hormones i.e., glucagon-like
peptide-1 (GLP-1) and peptide YY (PYY) [41,42]. Thus,
food containing high fiber content as in oat bran, flax,
celery etc., low sugar e.g. papaya, cranberries, bittergourd etc. and high water content e.g. Lettuce, tomato
etc. are recommended for diabetes management [43,44].
The diet alone can reduce glucose burden on the body,
thereby preventing excessive utility of anti-diabetic mo-
dalities and also delays insulin resistance. However, the
physiological response due to glucose homeostasis linked
with energy currency attributes, exercise/ physical work
in daily schedule is essential to channelize the energy
and also to revitalize the cells of the body. The combin-
ation of these two lifestyle modifications i.e., exercise
and diet can either reduce or delay the incidence of dia-
betes by over 50% [45].
The definite therapy for diabetes include target based
hypoglycemic drugs (by enhancing beta cell stimulation
or by reducing the gluconeogenesis etc.) alone or in
combination with insulin based on type and progression
of ailment over the years. There are five major classes of
oral antihyperglycemic drugs and a wide variety of insu-
lin (short acting / long acting) available for comprehen-
sive management of Diabetes. These five distinct classes
of oral antihyperglycemic drugs include the Sulfonyl-
ureas (SUs), Meglitinides, Biguanides, Thiazolidinediones
(TZDs)/glitazone, α-glucosidase inhibitors. These agents
fall into two broad categories based on mechanism of
action, which are “Secretagogues”, or drugs that aug-
ment insulin supply (sulfonylurea, non-sulfonylurea se-
cretagogues, and insulin); and “Sensitizers”, or drugs
that assist insulin action (biguanides, α-glucosidase in-
hibitors, and thiazolidinediones).
The commercially available drugs under these above-
mentioned categories, their physiological targets and
mode of action are given in Figure 1. Metabolic affects
of diabetes caused due to insulin deficiency are given in
Figure 2. It has also been reported that activated carbon
sphaeroides, by virtue of large specific area, fine porosity,
high mechanic strength and excellent adsorption abilities
allow intestinal absorption of glucose and thereby helps
in equilibrating blood glucose towards the more bal-
anced level [46].
Complications associated with anti-diabetic modalities
Around 3.2 million deaths (six deaths/minute) every year
is attributable to complications of diabetes; [26,27]. The
side effects or complications associated with diabetes
pharmacotherapy (synthetic drugs) can be divided into
three categories as: a) common side effects; b) uncom-
mon side effects and; c) rare side effects. The most com-
mon side effects associated with the oral hypoglycemic
drugs include hypoglycemia or extremely low blood
sugar (symptoms include profuse sweating, tremor,
shakiness, dizziness, hunger, mental confusion, coma,
and a rare risk of stroke or death), Gastrointestinal side
effects (abdominal pain, nausea, vomiting, diarrhea, gas-
siness, and bloating), edema (fluid in legs and ankles),
Figure 1 Various physiological targets of synthetic drugs; (1)-Meglitinides, Sulphonylureas [(Glimiperide (Amaryl); Glipizide (Glucotrol);
Glipizide-gits (Glucotrol-XL); Glyburide (Diabeta, Micronase); Glyburide micronized (Glynase); Tolbutamide (Orinase); Chlorpropamide
(Diabinese); Tolazamide (Tolinase); Acetoheximide (Dymelor)] & Phenylalanine derivatives; Repaglinide (Prandin) Nateglinide (Starlix),
act on pancreas to stimulate insulin secretion by blocking K + ions in β-cells, (2)- Biguanide & Thiazolidine diones act on liver to
decrease Gluconeogenesis; (3 & 4)- Biguanide Metformin (Glucophage, Riomet) Metformin-XR (Glucophage XR) act on muscle and
adipose tissue to augment peripheral glucose uptake & Thiazolidine diones (Rosiglitazone (Avandia) Pioglitazone (Actos) increase
insulin sensitivity via activation of receptors; (5) α-glucosidase inhibitors [(Acarbose (Precose) Miglitol (Glyset)] act on intestine to
delay glucose absorption.
Chawla et al. Journal of Diabetes & Metabolic Disorders 2013, 12:35 Page 4 of 16
http://www.jdmdonline.com/content/12/1/35increase in “bad” cholesterol (LDL). Certain uncommon
side effects include congestive heart failure, Anemia (low
red blood cell counts) and allergic reactions. On the
other hand, rare side effects/complications include
thrombocytopenia (low blood platelet counts), lactic
acidosis (build up of acid in the blood), leucopenia (low
white blood cell counts), macular edema (eye problems)
and liver disease/liver failure [47].
Herbal alternatives and management of diabetes
The purpose of this article is to examine the effect of
herbal medicines in the treatment of diabetes, focusing
on potential benefits and risks, and to provide sufficient
ways for the proper standardization of herbal drugs. The
associated complications of synthetic drugs have lead toa shift towards locating natural resources showing anti
diabetic activity. The Indian prehistoric literature reports
more than 800 plants with antidiabetic properties while
ethno pharmacological surveys indicate that more than
1200 plants can be used for hypoglycemic activity [48].
Herbs are also known to provide symptomatic relief and
aid in the prevention of the secondary complications of
the disease including cholesterol lowering action. Some
of these herbs have also been proven to help in the regen-
eration of β-cells and in overcoming insulin resistance. In
addition to maintaining normal blood sugar level, many
of these also possess antioxidant activity [24].
Herbal medicines can be broadly classified into the
following categories according to their mode of action:
a) drugs acting like insulin, b) drugs acting on insulin
Figure 2 Metabolism during diabetes.
Chawla et al. Journal of Diabetes & Metabolic Disorders 2013, 12:35 Page 5 of 16
http://www.jdmdonline.com/content/12/1/35secreting beta cells, c) drugs modifying glucose utiliza-
tion, d) drugs showing adrenomimeticism, e) pancreatic
beta cell potassium channel blockers, f ) cAMP (2nd
messenger) stimulators, g) renal glucose resorption in-
hibitors, , h) herbal drugs providing certain necessary el-
ements like calcium, zinc, magnesium, manganese and
copper for the beta-cells, i) drugs regenerating and/or
repairing pancreatic beta cells, j) effectors of size and
number of cells in the islets of langerhans, k) glyco-
genesis and hepatic glycolysis stimulators, l) drugs
preventing pathological conversion of starch to glucose
by inhibition of β –galactosidase, α–glycosidase & alpha-
amylase, m) drugs preventing oxidative stress that is
possibly involved in pancreatic ß-cell dysfunction found
in diabetes [24]; details of the same is given in the
Table 1.The plant constituents under the category of polysac-
charides, peptides, alkaloids, glycopeptides, triterpenoids,
amino acids, steroids, xanthones, flavonoids, lipids, phe-
nolics, coumarins, iridoids, alkyl disulphides, inorganic
ions and guanidines are reported to have antidiabetic
activity [48]. Alkaloids inhibit alpha-glucosidase and
decrease glucose transport through the intestinal epithe-
lium while imidazoline compounds and ferulic acid sim-
ulates insulin secretion in a glucose-dependent manner.
Polysaccharides, saponin, Triterpenoids, steroidal glyco-
sides cause increase in the levels of serum insulin, reduc-
tion in the blood glucose levels and improved tolerance
of glucose. In contrast flavonoids suppress glucose level,
reduce plasma cholesterol and triglycerides thereby, in-
creasing hepatic glucokinase activity by virtue of en-
hanced insulin release from pancreatic islets [48]. The vast
Table 1 Herbal plants showing antidiabetic activity
Botanical name Local name Mode of action Chemical constituents Marketed antidiabetic
product
Abies pindrow Morinda /
Rodha
Insulin secretagogue activity Volatile oil -
Abroma augusta Devil’s Cotton Lowering blood sugar Fixed oil, alkaloid -
Acacia arabica Babool Initiate release of insulin Arabin Madhumeha
Achyranthus aspera Chirchiri Decrease blood sugar - -
Agrimony eupatoria - Insulin releasing and insulin
like activity
- -
Ajauga iva Bugle Weed Decrease plasma glucose level - -
Allium sativum Lehsun Antihyperglycemic and
antinociceptive effect
Volatile oil, allin, allicin -
Allium cepa Pyaaz Stimulating effects on glucose





Aloe vera Gheequar - Aloin glycoside -
Aloe barbadensis Gheequar Stimulating synthesis and/or
release of insulin
Barbaloin, isobarbaloin, resin -
Amaranthus
spinosus
Kataili Chaulai - - -
Anacardium
occidentale






Kalmegh Increase glucose metabolism Diterpenoid lactone
andrographoloid
Diagon
Annona squamosa Sharifa Hypoglycemic, antihyperglycemic,





Artemisia pallens Davana Hypoglycemic, increases
peripheral glucose utilization
or inhibits glucose resorption
Essential oil, davanone -
Averrhoa bilimbi Bilimbi Increase serum insulin level - -
Azadirachta indica Neem Glycogenolytic effect due to






Beta vulgaris Chukandar Reduce blood glucose level




- Polyacetylenic glucoside -
Bixa orellana Annotta Increase plasma insulin conc. &
increase insulin binding on
insulin receptor
Oleo-resin -
Boerhaavia diffusa Punarnava Increase in hexokinase activity,
decrease in glucose-6-phosphatase
and fructose bis-phosphatase




Brassica juncea Rai Food adjuvants for
diabetic patients
Isothiocyanate glycoside




Karanju Free radicle scavenging Fatty oil -
Camellia sinensis Green Tea
(Chai)
Increase insulin secretion Polyphenolic constituents -
Capparis decidua Karer Hypoglycemic, antioxidant,
hypolipidaemic
- -
Mirch Capsaicin, pritein -
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Table 1 Herbal plants showing antidiabetic activity (Continued)
Capsicum
frutescens
Increase insulin secretion &
reduction of insulin binding
on the insulin receptor





- - Aavirai kudineer,
Madhumeha
Cassia auriculata Tarwar Increase utilization of glucose
through increase glycolysis
















Stimulate secretion of Insulin - -
Coriandrum
sativum
Dhania - Volatile oil, fixed oil, protein -
Coscinium
fenestratum
Jharhaldi Increase enzymatic antioxidants Barberine, glycoside, saponin -
Croton cajucara Jamalgota - Fixed oil -
Cryptolepis
sanguinolenta
Anantmul Increase glucose uptake
by 3T3-L1 cells
Cryptolepine -




Embellica officinalis Amla Reduce 5-hydroxymethylfurfural,
creatinine albumin level







& glucose 6 phosphatase
Swertiamarine glycoside Hyponidd, Glucolib,
Glucomap, Glucova




Eucalyptus Neel giri Increase insulin secretion
from clonal pancreatic beta
line (BRIN-BD 11)
Essential oil, cineol -
Euphrasia officinale Eyebright - - -
Ficus religiosa Peepal Initiating release of insulin Tannin -
Ficus bengalensis Bargad Rising serum insulin Tannin -
Ficus carica Anjir - - -
Gymnema
montanum
- Antioxidant & Antiperoxidative - -







Gentiana Olivier - Lowers plasma glucose level Iso-Orientin C-Glycoside -





- Lowers plasma glucose level - -
Vit. B, C, Fat -
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Helicteres isora Indian Screw
Tree
Decrease plasma triglyceride
level & insulin sensitizing activity
Saponin, tannin, lignin -
Hordeum vulgare Jau - - -
Hovenia dulcis - - Flavonoids -
Ipomoea aquatica Kalmisag - Carotene -
Ipomoea batata Shakarkand Reduce fasting blood sugar








Lupinus albus Turmas Lower Serum glucose level Alkaloid, fatty oil,
asparagines
-
Luffa aegyptiaca Ghiatori Lactigogue activity Fatty oil -
Leucas
lavandulaefolia
Kumbha Reduce Blood Glucose Level - -
Lagerstronemia
speciosa
Jarul - - -
Lepidium sativum Halim, Hurf - - -





Lower blood glucose level V.oil mirtii oleum -
Memecylon
umbellatum
Anjani Lower serum glucose - -
Momordica
cymbalania
Kadavanchi Reduce blood glucose level - -
Mucuna pruriens Kiwach Reduce blood glucose level - -














Morus indica - Increase glucose uptake - -
Murraya koeingii Curry Leaf Increase glycogenesis, decrease
glycogenolysis & gluconeogenesis
- Madhumeha
Nelumbo nucifera Lotus Reduce blood sugar level Nuciferin, nornuciferin -
Ocimum sanctum Tulsi Reduce blood sugar level V.oil, phenol, aldehyde,
fixed oil, alkaloid, tannin,
ascorbic acid
Glucoessential capsules
Olea europia Olive Potentiation of glucose, induced
insulin released and increase




Indian Fig - - -
Pandanus odorus Kevra Decrease plasma glucose level Essential oil -
Panax ginseng Pannag Lowering blood sugar level Glycans, panaxans I,J,K & L Glucoessential capsules
Punica granatum Anar Lowering blood sugar level Vitamin C, protein, tannin,
gallic acid, pelletierine
-
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Table 1 Herbal plants showing antidiabetic activity (Continued)
Picrorrhiza kurroa Katuka Decrease serum glucose Picrorrhizin, kutkin -
Phyllanthus amarus Bhui Amla Lowering blood sugar level Alkaloids Mersina
Phaseolus vulgaris Lobia Hypoglycemic, hypolipidemic,
inhibit alpha amylase activity,
antioxidant
- -













Syzygium cumini Jamun Decreases blood glucose level - Mersina, Diasulin, Diaveda,
Pancreas tonic, DWN-12,
Diabeta





Methi Decrease blood glucose
concentration





Tribulus terrestris Gokhru Decrease serum glucose Harmine Diaveda




Tinospora cardifolia Giloe Decrease blood glucose
and brain lipid
Berberine, starch Hyponidd, Mersina, Diagon,
Diasulin, Diaveda, Glucova,
Diabeta, Pancreas tonic
Tamarindus indica Imli - - -
Teramnus labialis Mashoni - Caumarin - fraxidin -
Urtifca dioica Bichhu Booti Increase Insulin secretion Fatty oil -
Viscum album Vadank Alpha glucosidase inhibitor - Glucoessential capsules
Vinca rosea Sadabahar Beta cell rejuvenation,
regeneration & stimulation
Vincristine, vinblastine Diabeta, Tincture of
panchparna







Increase glucose utilization Phenolics, caffeic acid -
Zingiber officinale Adrak Increase Insulin level &
decrease fasting glucose level
Sesquiterpene Diaveda
Zizyphus sativa Pitni-Ber Dose dependent reduction
in blood glucose level
Tannin Madhumeha
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cepted/scientifically validated herbal plants, traditional
herbal plants, antidiabetic plants that are under clinical tri-
als, as elucidated in Figure 3.
Contraindications of herbal alternatives
Herbal drugs are prescribed widely because of their ef-
fectiveness, less side effects, broad range of action and
relatively low cost. However, the non trial drugs are usu-
ally not evaluated for purity and consistency of active
compounds; they often contain contaminants and might
show batch-to-batch variations [49]. The exact mechanismof action in lowering blood sugar is often not known. In
addition, these herbs may not work well for everyone and
their overall effect may vary in individuals, due to lack of
standardization. Side effects can also be patient specific
and a combination of these herbs may be required to
obtain the desired effect which leads to the development
of pre-clinical trials for poly-herbal formulations. The vari-
ous shortcomings/contraindications of herbal medicines
includes: a) Being self prescribed, quality assurance is not
guaranteed and also may interact with other drugs, b) con-
traindications of herbal drugs and associated unusual
beliefs, c) contain powerful, pharmacologically active
Figure 3 Advancement in the field of anti-diabetic potential herbals (Extreme left: Traditional Herbs; Middle: Scientifically Validated,
yet not clinically proven; Extreme Right: Under clinical trials).
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interactions, d) usually cause hepatic and renal prob-
lems if taken in excess; due to lack of pharmacodynam-
ics and pharmacokinetics data and slow clearance rate
from the body, e) difficulty in identification of the
causative agent associated with the adverse reactions
encountered as these often contain multiple ingredients,
f ) lack of standardization while the formulation of
herbal drug i.e. delivery system for particular target is
generally not validated, g) mode of action of herbal
plant constituents is not clear enough to support thera-
peutic utility.
Complications refer to the changes or problems that
occur when treatment goes beyond the desired effect
and leads to unwanted symptoms. They can be mild or
severe varying from person to person. Usually complica-
tions/side effects arise in the case of chemical or syn-
thetic drugs. Herbal plants do not usually show any
adverse reactions, if tried and tested over a larger period
of human era. Whereas due to lack of standardization,
pharmacological and toxicological evaluation, certain
undesired effects might develop as a result of intake of
non standardized herbal formulations. Such effects are
generally due to the presence of contaminants/adulter-
ants rather than the active constituent itself. These con-
traindications develop as a physical condition that put
some people at risk of danger from using a particular
herbal formulation and results in ironical situation of
benefit vs. risk [9].Safety of herbal medicines is of major concern,
whether being self-prescribed or used to treat minor and
chronic conditions. However, most patients consuming
herbal preparations are not aware of the potential ad-
verse effects these preparations [49]. It is essential to as-
certain that certain groups of the population especially
pregnant and nursing women should be extra cautious
as they are more susceptible to herbal adverse reactions
or toxicities. Some compounds in herbs can cross the
placenta and are clearly linked to birth defects or other
problems in newborns. Thus, the safety against terato-
genic effects should also be evaluated during pre clinical
studies. Children and infants are much more sensitive
than adults to the effects of all medicines including
herbs [50,51]. The elderly with cardiovascular problems,
diabetes and other chronic diseases may show exagger-
ated toxic/adverse reactions to herbs. The key to such
associated limitations of herbal drugs is to standardize
them prior to use commercially.
Standardization approaches for herbal drugs
Standardization and quality control of herbals is a pro-
cess involving monitoring of the entire process of
bioprosception of natural flora, collection, extraction,
bio-activity guided fractionation and formation of herbal
drugs [1,22] utilizing existing technical standards [52].
Standardization of herbal medicines is the process of
prescribing a set of standards or inherent characteristics,
constant parameters, definitive qualitative and quantitative
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and reproducibility [53,54]. The quality of herbal drugs is
affected by numerous factors: a) Mixtures of many con-
stituents that make physiological responses complex yet
holistic; b) Active principle (s) are generally unknown;
c) Non-availability of selective analytical methods or
standard reference compounds limits development of
standard chemical fingerprint, required to ascertain
efficacy among various batches; d) Natural variability
associated with plants both in wild & non-wild var-
ieties; e) Differences in spectra of bioactivity in natural
vs. chemo-varieties and chemo cultivars and; f) Variability
in source and quality of the raw material etc.
The methods used in harvesting, drying, storage,
transportation, and processing (for example, mode of ex-
traction and polarity of the extracting solvent, instability
of constituents, etc.) also affect significantly the finished
herbal drugs. Unknown compositions and site of targets,
batch-to-batch variations and non-standardized methods
of development of herbal drugs restricts its commercial
utility [8]. All these factors influence the bio-efficacy and
reproducible therapeutic effect of herbal drugs. The sci-
entifically validated drugs for diabetes mellitus (Figure 3)
require adoption of proper standardization methodolo-
gies to ensure its efficacy for human use.
Proposed models in meeting challenges of
standardization process
The traditional medicine were prescribed by rishis since
vedic times specific to a patient or a group of patients
based on locally available flora. Accordingly, this science
has evolved in many centuries to the present age of
ayurveda, unani, siddha etc. The present day bulk re-
quirement of drug while covering many ethnic groups of
global population poses a great challenge towards stand-
ardizing ’standardisation methodologies’. It requires
state-of-art technologies to ensure that finished product
is safe to use and reproducible to ensure adequate sup-
ply. One of the accepted approaches is to ascertain spe-
cified amount of active ingredient- for e.g., 30-80% of
silymarin or silybin in Milk thistle (Silybum mariannum)
or 30-70% of kavalctones in Kava (Piper methysticum) etc.
Challenges in identifying ‘marker compounds’ and
‘active principle(s)’
The major challenge is that ‘active principle’ is not ne-
cessarily always a ‘marker’ compound. Markers are often
chosen to identify correct species as in Echinacea
angustifolia could be represented by echinacoside;
Parthenolide for Feverfee, Tanacetum parthenium repre-
sents its particular chemotype. Ferulic acid is used as a
stability marker to ascertain storage conditions. Frac-
tionation defines the process to reach towards peak of
one or two compounds referred as marker and if takenisolated compound, it has been observed that there is a
substantial loss of activity and increased toxicity. If there
is one compound as standardized marker, the extract
could be spiked with pure chemical to ascertain ‘false’
clearance from solving the issue of ‘batch-to-batch’ vari-
ation. Thus, various constituents of an extract should be
represented by (a) Active principle (s); (b) Active marker
(s); (c) Analytical marker (s) and; (d) Negative marker(s).
However, it is not possible that in all standardization
processes, all such markers are available. In addition,
these markers/active principle (s) based standardization
itself, creates confusion to ascertain a particular bioactiv-
ity profile. It can be understood by the fact that most of
natural plant products are standardized by active
markers, contributing to efficacy, though clinical efficacy
yet to be correlated while rest of commercially available
herbal drugs are having analytical markers with defined
range of a particular constituent and negative markers
are used to screen toxicological aspects. However, the
analytical markers represented as ‘total alkaloids content’
provide another mislead as it might be representing a
complete set of constituents rather than ‘specific’ con-
stituent itself. The marker content also varies in different
seasons of growth, sites of growth and other environ-
mental factors. Any variation is storage or processing
method will also cause shift in levels of markers. In
addition, at industrial level, raw material is mixed lead-
ing to ‘average marker content’ rather than absolute
marker level as being standardized in laboratory with
controlled amount of raw material. Thus, it is essential
to standardization of ‘average marker content’ is abso-
lute necessity prior to shifting to field level production.
Normalisation of data is essential to adjust the concen-
tration of marker component with respect to various re-
cipients being added or altering the extraction ratio.
Extraction ratio refers to the weight of the plant used as
raw material with respect to the yield generated. Frac-
tionation will generate high strength extracts refers to
extraction using more selective and less polar solvents
while the remaining extract residue will become stan-
dardized extract. Thus, it is important to understand
that a particular process required to be defined with a fi-
nite point wherein the process should be stopped as fur-
ther fractionation is causing loss of activity. At present,
there are no methodologies that can correlate ‘activity
profile’ vs. ‘constituent’s profile’ as being expected from
herbal drugs to act [55-58].
Challenges in developing technical standards for
standardization process
It is essential to employ different sets of technical stan-
dards for proposed standarisation models. The import-
ant standards include Pharmacopeial Quality Standards;
Marker based on Phytochemical Assays and bioactivity
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Standards; Poly herbal reference standards and Chemi-
informatic approaches based structural standards that
have been given in Table 2.
Meeting challenges by employing quality control measures
Quality control measures include right from the proper
identification of plants, season and area of collection as
well as their extraction and purification processes. Some
of the important tests conducted for ensuring quality
process include.
Macro and microscopic examination The examination
is conducted to ascertain taxonomical classification of
source (wild/agriculture) and part of plant being to tar-
get so that defined search of adulterants based on a
levels of exposure to environment can be evaluated. The
plant part under consideration required to be standard-
ized with respect to its variable factors for selection e.g.
if leaf is selected as target plant part, leaf constant based
on the palisade ratio, vein islet number, vein termination,
stomatal number, stomatal index and type of trichomes
and stomata should be evaluated [22].
Removal of foreign organic matter This involves re-
moval of foreign organic matter other than source plant
to get the drug in pure form.
Ash values Thermo gravimetric analysis (TGA), differ-
ential thermal analysis (DTA) and differential scanning
calorimetry (DSC) provides information about physical
or chemical changes [59-61] and it also provides esti-
mates of total ash, sulphated ash, water soluble ash and
acid insoluble ash etc.Table 2 Existing/ Proposed standards for herbal drug standar
Type Tests/Applications/Standards use
Pharmacopeia standards Microscopic examination; Authentic
Pesticide Residue; Density; Specific
Heavy metals
Marker based phytochemical assays Active principle(s), Storage marker(s
Solvent System Standardisation, Ph
available/ synthetically viable; Chro
Process control markers Batch analysis intermediate testing,
check procedural standards, Start a
Storage standards Storage standard marker for raw m
authentication; In process storage o
finished products); Storage standar
characteristics, labeling standards fo
Poly herbal reference standards Component based single constitue




Activity descriptors and its correlati
Pharmacophore standards using HeMoisture content Moisture content is required to be
evaluated precisely to determine actual weight of drug
material. Low moisture suggests better stability against
degradation of product.
Extractive values Several techniques are being used in
extraction of phytochemicals. These include supercritical
fluid extraction [62,63], microwave assisted extraction
[64-66], and solid phase extraction [67,68]. These are in-
dicative weights of the extractable chemical constituents
of crude drug under different solvent environment.
Qualitative chemical evaluation It includes identifica-
tion and characterization of crude drug with respect to
phytochemical constituent like phenolics, alkaloids, fla-
vonoids, dietary fiber etc. Phytochemical screening tech-
niques involve botanical identification, extraction with
suitable solvents, purification, and characterization of
the active constituents of pharmaceutical importance
[69]. Differential pulse polarography (DPP) can also be
used to study trace amounts of chemicals with detection
limits on the order of 10-8 M. A DPP method is available
for the determination of total hypericin in phyto-
therapeutic preparations (drops, tablets and capsules) in
various buffer systems over the pH range 3.5–10.0 [70].
Chromatographic examination Characterization of the
different chemicals on the basis of their interaction with
the mobile phase using preparative high performance li-
quid chromatography (HPLC)- low pressure HPLC (typ-
ically under 5 bar) and high pressure HPLC (pressure
>20 bar). Liquid chromatography- mass spectroscopy
(LCMS) has become method of choice in many stages
of drug development as it provides direct chemical fin-
gerprint in correlation with desired bioactivity. Chemicaldisation
d
ity; Quality; Extractive Value; Foreign Matter; Microbial count;
Gravity; Loss on drying; Melting point; Viscosity; Refractive Index;
), Chemical family representing a particular species, chemotype,
armacopeia standards with respect to reference compound commercially
matographic, IR, MS, UV, NMR based chemical profile marking
Identification tests, Process induced toxicity/ impurity- quality
nd Close time point average run sample marker(s)
aterial (conditions standardization); specimen collection and
f stable intermediate metabolites from fractions (remained stable till
ds for processed material and stability, shelf life and container
r finished product
nt reference standard exclusive and retained its profile in poly herbal
nutritional aid as supplement, Therapeutic standards for efficacy of
on modeling with poly-constituent profile based indicators;
rbal QSAR approaches to identify structural requirements
Figure 4 Integrated herbal drug development standardisation model [Single Constituent based Herbal Medicine; Poly constituent Herbal
Drug (based on Chemiinformatics Approaches); Poly herbal formulation; Herbal Drug Development using Reverse Pharmacology].
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http://www.jdmdonline.com/content/12/1/35standardization of an aqueous extract of the mixture of
the 20 herbs provided 20 chemical compounds serving
as reference markers using LC-MS [71,72]. Suchstandards will be used to develop poly-herbal formula-
tions. Gas chromatography (GC) and gas chromatography-
mass spectroscopy (GC-MS) based headspace solid-phase
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reported for analysis of the volatile compound [73,74].
Quantitative chemical evaluation Analysis of the
amount of the major classes of active constituents. X-ray
powder diffractometry (XRD) is used to analyse different
minerals, crystalline materials and metallic based herbal
formulations. The tin based herbal drug Vanga Parpam
was estimated by XRD and the intense sharp diffraction
peaks clearly confirmed the presence of high crystallinity
in Vanga Parpam [75]. X-ray powder Diffraction data
confirmed the formation of phospholipid complex with
emodin [76] and naringenin [77].
Toxicological studies It reveals level of pesticide resi-
dues and potentially toxic elements. Safety studies in an-
imals generate LD50 value and other applied pre-clinical
toxicity results as per the requirements of drug regula-
tions. HPTLC technique is widely employed in pharma-
ceutical industry in process development, identification
and detection of adulterants in herbal product and helps
in identification of pesticide content, mycotoxins as well
as quality control of herbs and health foods [78,79].
Microbial assay To establish the absence or presence of
potentially harmful microorganisms. It often includes
total viable content, total mold and enterobacterial
counts. Certain minimum standards are set by different
monitoring agencies [80,81].
Integrated herbal drug development model
India, with pluralistic health care system, having exten-
sive expertise in modern medicine, Indian systems of
medicine, and life & pharmaceutical sciences with an ap-
proach towards observational therapeutics is an ante-
cedent path towards reverse pharmacology in natural
drug development as being proposed [5]. The chemi-
informatics based drug development approaches re-
quired to be integrated with existing Reverse Pharmaco-
logical Approach utilizing above-mentioned technical
standards at each stage of process. The classical ap-
proach of Bioactivity guided fractionation/identification
of leads required to be amalgamated with these modern
approaches of natural drug development. Based on this
study, we hereby propose an integrated model of herbal
drug development model using a) Classical Approach of
Ayurvedic Therapeutics (Active principle guided ap-
proach); b) Reverse Pharmacological Approach based on
Observational Therapeutics; c) Technical Standards for
complete product cycle; d) Chemi-informatics, Herbal
Qualitative Structure Activity Relationship (QSAR) and
Pharmacophore modeling; e) Post Market Analysis
(Figure 4). This model could be used to convert the
herbal products identified in scientifically validatedcategory (Figure 3) to herbal drugs for holistic man-
agement of diabetes.
Conclusions
Herbal drug standardization is a dynamic phenomenon
requires inputs from various branches of life sciences in-
cluding botanists, plant physiologists, pharmacology,
pharmacogonasy, chemiinformatics, biochemistry, toxi-
cology, biotechnology, drug development, natural me-
dicine (Ayurveda, Unani, Siddha etc.) and industrial
economic/regulatory affairs. An in depth analysis of each
step/stage during natural drug development is neces-
sary to ascertain quality, safety and reproducibility. The
complexity of chronic diabetes or lack of awareness
leads to sudden onset of diabetes poses a significant risk
of occurrence of ketoacidosis and diabetic coma, if
untreated/unnoticed respectively. The multi-organ dys-
function syndrome arises through this metabolic disorder
can be mitigated/delayed by utilizing holistic approach of
herbal drugs, only if these drugs (scientifically validated)
undergo a critical standardization process. The proposed
model is a key to meet some of the probable chal-
lenges of this arena. Further studies are warranted to
ensure that an effective herbal drug standardization
methodology will be developed, backed by a regulatory
standard guide the future research endeavors in more
focused manner.
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